Companies Get 19 EU Paediatric Extensions in 2016, But Many Firms Miss Trial Completion Deadlines
Executive Summary
A report from the European Medicines Agency shows that in 2016, 19 products were awarded a six-month extension of their supplementary protection certificate for conducting pediatric trials, while the amount of scientific advice offered for pediatric medicines continued to rise.
You may also be interested in...
Norway To Grant Pediatric Extensions Of SPCs From Sept. 1
Norway has acted swiftly to amend its national legislation to allow six-month pediatric extensions to supplementary protection certificates as of Sept. 1, when the EU Paediatric and SPC Regulations will take effect in the country. Also, transitional arrangements have been put in place that will allow certificates expiring between March 1 and Aug. 31 to become valid again.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.